Rivernorth Capital Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Rivernorth Capital Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-65,707	Closed	-$97K	–	834
2021 Q4	$97K	Sell	65,707 -23,889	-27%	-$33.3K	﹤0.01%	497
2021 Q3	$133K	Buy	89,596 +23,889	+36%	+$25.5K	0.01%	387
2021 Q2	$76K	Hold	65,707	–	–	﹤0.01%	420
2021 Q1	$54K	Hold	65,707	–	–	﹤0.01%	403
2020 Q4	$95K	Sell	65,707 -31,003	-32%	-$38.9K	0.01%	310
2020 Q3	$114K	Buy	+96,710	New	+$97.8K	0.01%	269

Other funds holding JSPRW

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Rivernorth Capital Management's JSPRW Position: Q1 2022 in Review

Rivernorth Capital Management sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2022, closing a stake of 65,707 shares — an estimated $97K sold.

Rivernorth Capital Management first reported a position in JSPRW in Q3 2020 and held it in 6 quarters. The position peaked at $133K in Q3 2021. 15 funds tracked by Wall St. Rank hold JSPRW as of Q1 2022.

Rivernorth Capital Management reported no remaining Japer Therapeutics Warrants position as of Q1 2022 after selling out during the quarter.
Rivernorth Capital Management sold 65,707 Japer Therapeutics Warrants shares in Q1 2022, an estimated $97K.
Rivernorth Capital Management first reported a position in Japer Therapeutics Warrants in Q3 2020 and held it in 6 quarters.
Rivernorth Capital Management's Japer Therapeutics Warrants position peaked at $133K in Q3 2021.
15 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.